期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿哌沙班在心房颤动患者卒中预防中的应用

Application of apixaban in stroke prevention in patients with atrial fibrillation
原文传递
导出
摘要 心房颤动（atrial fibrillation，AF）是卒中的独立危险因素。AF患者的卒中转归较差，致死率和致残率也较高。对于卒中风险较高的AF患者，需要应用抗凝药。阿哌沙班是近年来新出现的一种口服直接Xa因子抑制药。与华法林等传统抗凝药相比，阿哌沙班在预防AF患者卒中和全身性栓塞方面展现出一定的优势。 Atrial fibrillation （AF） is an independent risk factors for stroke. The stroke outcome in patients with AF is poor. The mortality and morbidity were also higher. As for the higher risk of stroke in patients with AF, the application of anticoagulant drugs is needed. Apixaban is an emerging oral direct X a factor inhibitor in recent years. Compared to the traditional anticoagulants, such as warfarin, apixaban shows certain advantages in the prevention of stroke and systemic embolism in patients with AF.
作者 姜明静 曹立颖 刘宁
机构地区 兰州大学第一临床医学院 兰州大学第一医院神经内科
出处 《国际脑血管病杂志》 北大核心 2012年第7期524-527,共4页 International Journal of Cerebrovascular Diseases
关键词 心房颤动 卒中 抗凝药 因子Xa 阿哌沙班 华法林 Atrial Fibrillation Stroke Anticoagulants Factor Xa Apixaban Warfarin
分类号 R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献39

  • 1Lip GY, Tse HF. Management of atrial fibrillation. Lancet, 2007, 370: 604-618.
  • 2Roger VL, Go AS, Lloyd-Jones DM, et aI; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation, 2012, 125: e2-e220.
  • 3Go AS, Hylek EM, Phillips KA, et aI. Prevalence of diagnosed atrial fibrillation in adults: national imp Iications for rhythm management and stroke prevention: the Anf'icoagnerion and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285: 2370-2375.
  • 4Hannon N, Sheehan 0, Kelly L, et al. Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis, 2010, 29: 43-49.
  • 5Marini C, De Santis F, Sacco S, et aI. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a popula?tion-based study. Stroke, 2005, 36: 1115-1119.
  • 6Wann LS, Curtis AB, January CT, et aI; ACCF/AHAIHRS. 2011 ACCF/AHAIHRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation! American Heart Association Task Force on Practice Guidelines. J Am Coli Cardiol, 2011,57: 223-242.
  • 7Reynolds MW, Fahrbach K, Hauch 0, et aI. Warfarin anticoagila?tion and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest, 2004,126: 1938-1945.
  • 8Lassen MR, Raskob GE, Gallus A, et aI. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med, 2009,361: 594-604.
  • 9Lassen MR, Raskob GE, Gallus A, et aI; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee repJacement (ADVANCE-2): a randomised double-blind trial. Lancet, 2010,375: 807-815.
  • 10Pinto DJ, Orwat MJ, Koch S, et aI. Discovery of 1-(4-methoxy?phenyl)-7-oxo-6-( 4-(2-oxopiperidin-l-yl) phenyl )-4,5,6, 7-tetra?hydro-lH-pyrazolo [ 3, 4-c J pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chern, 2007, 50: 5339-5356.

二级参考文献1

共引文献1400

国际脑血管病杂志
2012年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部